Short-term benefit of smoking cessation along with glycopirronium on lung function and respiratory symptoms in mild COPD patients: a retrospective study
- 6 August 2018
- journal article
- research article
- Published by IOP Publishing in Journal of Breath Research
- Vol. 12 (4) , 046007
Abstract
Introduction. Tobacco smoke is the leading cause of chronic obstructive pulmonary disease (COPD). Smoking cessation can change the natural history of COPD, as we know from the GOLD guidelines. Little is known about the short-term clinical and functional effects of smoking cessation treatment combined with anti-muscarinic bronchodilators. Objective. To determine whether quitting smoking, obtained by smoking cessation treatment combined with the use of a new long-acting muscarinic antagonist bronchodilator (LAMA), can improve lung function tests and respiratory symptoms more than the use of LAMA alone. Methods. We evaluated, in a retrospective analysis, the functional and clinical data, collected in one year, of 120 patients who were current smokers affected by mild COPD and who quit smoking using smoking cessation treatment combined with glycopirronium. We compared them with a group of 80 patients with mild COPD undergoing the same treatment but who did not quit smoking. All patients underwent functional and clinical tests at baseline and at a third-month check. Measurements and main results. The two groups were homogeneous in terms of demographic data without significant differences. All patients used varenicline for smoking cessation. They all performed the following tests: a spirometry with detection of resistances, the 6 min walking test, haemogasanalysis, the exhaled CO test, the COPD assessment test (CAT) and finally the modified Medical Research Council test (mMRC). A significant improvement in the functional tests at the third-month check was found in both groups—quitters and non-quitters. However, a notable increase in the examined parameters was registered in the group of patients who quit smoking, in particular, we observed a significant increase at the third-month check of the parameter forced expiratory volume in 1 s (FEV1) of more than 200 ml with p < 0.001. A comparison between quitters and non-quitters revealed a major benefit derived from smoking cessation in terms of functional changes and symptom relief. In particular, not only FEV1 but also forced expiratory flow at 25%–75% of vital capacity (FEF 25–75) ( p < 0.01) and CAT ( p < 0.001) were found to be significantly improved in patients who quit than in patients who did not at the check time point. Conclusions. Smoking cessation treatment obtained by varenicline was confirmed as a crucial therapeutic option, especially when combined with bronchodilator in mild COPD. Patients who quit smoking could already benefit from both treatments in the short term, improving lung function and respiratory symptoms and therefore improving their quality of life.Keywords
This publication has 35 references indexed in Scilit:
- Is The CAT Questionnaire Sensitive To Changes In Health Status In Patients With Severe COPD Exacerbations?COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012
- Symptom variability in patients with severe COPD: a pan-European cross-sectional studyEuropean Respiratory Journal, 2010
- Bronchodilators accelerate the dynamics of muscle O2 delivery and utilisation during exercise in COPDThorax, 2010
- Cigarette Smoke, Inflammation, and Lung Injury: A Mechanistic PerspectiveJournal of Toxicology and Environmental Health, Part B, 2009
- Standardisation of lung function testing: helpful guidance from the ATS/ERS Task ForceThorax, 2006
- Do pharmacy staff recommend evidenced-based smoking cessation products? A pseudo patron studyJournal of Clinical Pharmacy and Therapeutics, 2006
- Chronic obstructive pulmonary disease: current burden and future projectionsEuropean Respiratory Journal, 2006
- Long‐acting β2‐adrenergic formoterol and salmeterol induce the apoptosis of B‐chronic lymphocytic Leukaemia cellsBritish Journal of Haematology, 2003
- Chronic obstructive pulmonary disease: molecular and cellularmechanismsEuropean Respiratory Journal, 2003
- Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary diseaseThorax, 1999